Several clinical trials have explored the clinical benefit of histone deacetylase (HDAC) inhibitors in combination with DNA methyltransferase (DNMT) inhibitors for AML patients (17, 18). This evidence concerns the gene HDAC9 and acute myeloid leukemia.